SCHEMBL4686394

SCHEMBL4686394

OCCSc1ccccn1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.62
KMT2A Q03164 3/20 0.57
MAPT P10636 2/20 0.57
EHMT2 Q96KQ7 1/20 0.52
EHMT1 Q9H9B1 1/20 0.52
APOBEC3G Q9HC16 1/20 0.52
NPC1 O15118 6/20 0.49
RAB9A P51151 6/20 0.49
MEN1 O00255 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
PKM P14618 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
SMN1; SMN2 Q16637 5/20 0.48
HPGD P15428 4/20 0.48
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
POLB P06746 2/20 0.47
LMNA P02545 1/20 0.47
HSD17B10 Q99714 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL679871 0.88 ALDH1A1 (0.59) ALDH1A1KMT2AMAPTEHMT2EHMT1
SCHEMBL4687627 0.86 ALDH1A1 (0.57) ALDH1A1KMT2AMAPTEHMT2EHMT1
SCHEMBL4684788 0.85 ALDH1A1 (0.56) ALDH1A1KMT2AMAPTEHMT2EHMT1
SCHEMBL4685852 0.85 ALDH1A1 (0.56) ALDH1A1KMT2AMAPTEHMT2EHMT1
SCHEMBL21147975 0.84 APOBEC3G (0.55) ALDH1A1KMT2AMAPTEHMT2EHMT1
SCHEMBL4687322 0.83
SCHEMBL7208033 0.81 ALDH1A1 (0.59) ALDH1A1KMT2AMAPTEHMT2EHMT1
SCHEMBL29362629 0.80 EHMT2 (0.59) ALDH1A1KMT2AMAPTEHMT2EHMT1
SCHEMBL126713 0.80 EHMT2 (0.59) ALDH1A1KMT2AMAPTEHMT2EHMT1
SCHEMBL10404144 0.80 ALDH1A1 (0.54) ALDH1A1KMT2AMAPTEHMT2EHMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250075147-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS OSMO LABS, PBC 2025-03-06 US claimed
CN-115252810-A Variable-form camptothecin polypeptide nano preparation and preparation method and application thereof 安徽中医药大学 2022-11-01 CN claimed
EP-0177907-B1 2-PYRIDINE-THIOL DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Richter Gedeon Vegyészeti Gyár R.T. (HU) 1988-06-01 EP claimed
US-20250075147-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS OSMO LABS, PBC 2025-03-06 US disclosed
EP-3426246-B1 THIAZOLIDINONE COMPOUNDS AND USE THEREOF NATIONAL HEALTH RES INST (TW) 2024-05-01 EP disclosed
CN-114404417-B Dendritic polypeptide-camptothecin drug conjugate and preparation method and application thereof 广东晨康生物科技有限公司 2023-06-13 CN disclosed
CN-115252810-A Variable-form camptothecin polypeptide nano preparation and preparation method and application thereof 安徽中医药大学 2022-11-01 CN disclosed
CN-114404417-A Dendritic polypeptide-camptothecin drug conjugate as well as preparation method and application thereof 佛山市晨康生物科技有限公司 2022-04-29 CN disclosed
CN-114402096-A Composition for tin-silver alloy electroplating comprising complexing agent 巴斯夫欧洲公司 2022-04-26 CN disclosed
CN-108883099-B Thiazolidinone compounds and use thereof 石全 2021-09-28 CN disclosed
WO-2021052817-A1 COMPOSITION FOR TIN-SILVER ALLOY ELECTROPLATING COMPRISING A COMPLEXING AGENT BASF SE (DE) 2021-03-25 WO disclosed
EP-0620003-B1 VASOPRESSIN ANTAGONIST AND OXYTOCIN ANTAGONIST OTSUKA PHARMA CO LTD (JP) 2008-01-16 EP disclosed
EP-1748987-A2 2-PROPENE-1-ONES AS HSP 70 INDUCERS Torrent Pharmaceuticals Ltd (IN) 2007-02-07 EP disclosed
WO-2005097746-A2 2-PROPENE-1-ONES AS HSP 70 INDUCERS TORRENT PHARMACEUTICALS LTD (IN) 2005-10-20 WO disclosed
US-20030073862-A1 Compounds BIOVITRUM AB (SE) 2003-04-17 US disclosed
WO-2003004458-A1 NEW COMPOUNDS BIOVITRUM AB (SE) 2003-01-16 WO disclosed
US-5753644-A Vasopressin antagonist and oxytocin antagonist OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1998-05-19 US disclosed
US-5622947-A VASODILATORS, HYPOTENSIVE AGENTS, DIURETICS, PLATELET AGGLUTINATION INHIBITORS; ALSO USED TO PREVENT PREMATURE BIRTH, TREAT DYSMENORRHEA OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1997-04-22 US disclosed
EP-0620003-A1 VASOPRESSIN ANTAGONIST AND OXYTOCIN ANTAGONIST OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1994-10-19 EP disclosed
US-4713388-A Certain 3- or 4-benzoyl-2-[(2-aminoethyl)thio-pyridines] and their anti-ulcer properties RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 1987-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073862-A1 Compounds PPARG, PPARA, PPARD ALDH1A1 383/4885KMT2A 1939/4885MAPT 4479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.